Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: micdundee2 who wrote (35067)	7/10/2007 6:14:58 PM
From: Bucky Katt	Read Replies (2) \| Respond to of 48461

Of medical interest> CHICAGO (Reuters) - Tiny bubbles injected in mice delivered potent cancer drugs to tumors without harming surrounding tissue, a U.S. researcher said on Tuesday, in a finding that may lead to new targeted cancer therapies. The technique uses ultrasound imaging to track the drug in the body and release it with a pop once it has reached its target. "Imagine soap bubbles," said Natalya Rapoport of the University of Utah's Department of Bioengineering. "Now imagine a drug in the soap bubbles." When injected in the bloodstream, these tiny bubbles loaded with the chemotherapy drug doxorubicin seek out cancer tumors and congregate. "These nanobubbles don't penetrate normal blood vessels but they do penetrate blood vessels in the tumor," said Rapoport, whose study appears in the Journal of the National Cancer Institute. Once in the tumor, the nanobubbles combine to form larger "microbubbles," which can be seen on an ultrasound. "When these bubbles accumulate, I give strong ultrasound radiation to the tumor to blow them up," she said in a telephone interview. "Then the drug gets out of these bubbles locally at the tumor site." In mice, the nanobubbles were more effective at blocking tumor growth than other nanoparticle delivery methods. "So far, we tried it in mice with human breast cancer tumors. We got very promising results," she said. Rapoport will test the therapy in larger animals and hopes to start human clinical trials in three years.

To: micdundee2 who wrote (35067)	7/10/2007 6:18:24 PM
From: Bucky Katt	Respond to of 48461

Subprime KaBoom> Moody's Lowers Ratings on Subprime Bonds, S&P May Cut (Update1) July 10 (Bloomberg) -- Moody's Investors Service lowered the credit ratings on $5.2 billion of bonds backed by subprime mortgages and Standard & Poor's said it may cut $12 billion of securities after criticism they waited too long to respond to rising home-loan defaults. Moody's cut ratings on 399 bonds issued in 2006 and said it may reduce rankings on another 32. S&P is preparing to lower the ratings on 2.1 percent of the $565.3 billion of subprime bonds issued from late 2005 through 2006, citing a deepening housing slump. U.S. Treasuries rose, the dollar slumped and financial company shares led stocks lower. Ratings changes ``are going to force a lot more people to come to Jesus,'' said Christopher Whalen, an analyst at Institutional Risk Analytics in Hawthorne, California. ``When a ratings agency puts a whole class on watch, it will force all the credit officers to get off their butts and reevaluate everything. This could be one of the triggers we've been waiting for.'' `Global Universe' The actions would be the biggest ever in the subprime market, the companies said. Insurers and pension funds may be among investors required to sell their bonds if they are downgraded, potentially driving down prices of $800 billion in subprime mortgages and $1 trillion of collateralized debt obligations, which package mortgage bonds into new securities. S&P said it is also reviewing the ``global universe'' of CDOs that contain subprime mortgages. Investors in CDOs alone stand to lose as much as $250 billion, according to Institutional Risk Analytics, which writes computer programs for auditors. S&P made its announcement before U.S. stock markets opened for trading. Moody's followed after the markets closed.